Jazz Pharma Stock Hits All-Time High After FDA Approves Ziihera for Stomach Cancer

The FDA has approved Jazz's Ziihera as a first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma, establishing a new standard of care.